Acute falciparum malaria Infections and Infestations Plasmodium falciparum malaria
Conditions
Interventions
Current interventions as of 22/02/2010:
Arm 1 (N = 40): receive artesunate alone at a dose of 6 mg/kg/day for seven days
Arm 2 (N = 40): receive artesunate alone at a dose of 6 mg/kg/day in two divide
Sponsors
University of Oxford (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Children greater than 6 years old and adults (either sex) presenting with acute falciparum malaria will be eligible for this study provided that: 1. They or their parents/guardians give fully informed consent 2. They have not received antimalarial drugs in the previous 48 hours 3. Plasmodium falciparum parasitaemia exceeds 10,000 /uL 4. They agree to seven days of hospitalisation
Exclusion criteria
Exclusion criteria: 1. Pregnancy 2. Microscopy indicates a mixed infection 3. History of allergy to artesunate or mefloquine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parasite clearance times in relation to artesunate/dihydroartemisinin (DHA) plasma concentration (PK/PD) (time point: 63 days). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cure rates (time point: 63 days) 2. In vitro sensitivity of P. falciparum to artesunate measured prior to treatment (time point not applicable) 3. Molecular markers of drug resistance measured prior to treatment (time point not applicable) | — |
Countries
Cambodia, Thailand
Outcome results
None listed